脑脊液免疫细胞因子可预测非小细胞肺癌脑转移患者颅内肿瘤对免疫疗法的反应

IF 7.2 2区医学

Oncoimmunology Pub Date : 2023-12-07 DOI:10.1080/2162402x.2023.2290790

Meichen Li, Jing Chen, Hui Yu, Baishen Zhang, Xue Hou, Honghua Jiang, Dan Xie, Likun Chen

引用次数: 0

摘要

免疫疗法对脑转移的非小细胞肺癌（NSCLC）患者有颅内疗效。然而，免疫疗法颅内反应的预测性生物标志物还很缺乏...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases

Immunotherapy has shown intracranial efficacy in non-small cell lung cancer (NSCLC) patients with brain metastases. However, predictive biomarkers for intracranial response to immunotherapy are lac...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.